InvestorsObserver
×
News Home

Is it Time to Dump Altimmune Inc (ALT) Stock After it Has Risen 2.58% in a Week?

Wednesday, November 30, 2022 11:47 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Altimmune Inc (ALT) Stock After it Has Risen 2.58% in a Week?

Altimmune Inc (ALT) stock is up 2.58% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Altimmune Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALT!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ALT Stock Today?

Altimmune Inc (ALT) stock is trading at $9.55 as of 11:47 AM on Wednesday, Nov 30, a rise of $0.09, or 0.95% from the previous closing price of $9.46. The stock has traded between $9.37 and $10.09 so far today. Volume today is less active than usual. So far 275,606 shares have traded compared to average volume of 1,060,353 shares.

More About Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Click Here to get the full Stock Report for Altimmune Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App